Biomarkers of Uremic Cardiotoxicity

Related Experiment Video

Updated: Oct 19, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.2K

Bojan Stopic1, Sandra Dragicevic2, Branislava Medic-Brkic3

  • 1Clinical Department for Nephrology, Zvezdara University Medical Center, Dimitrija Tucovica 161, 11000 Belgrade, Serbia.

Toxins
|September 26, 2021
PubMed

Insights

Cardiovascular disease risk increases with chronic kidney disease (CKD). Serum albumin, urea, and interventricular septum thickness are key predictors of cardiovascular events in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarker Research

Background:

  • Cardiovascular (CV) disease is a major complication of chronic kidney disease (CKD).
  • Early detection of CV risk in CKD patients is crucial.
  • Novel cardiotoxicity biomarkers are being investigated.

Purpose of the Study:

  • To identify novel biomarkers for early detection of cardiotoxicity in CKD patients.
  • To analyze potential biomarkers including inflammation, oxidative stress, acute kidney injury, and microRNAs.
  • To assess CV risk predictors in non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD populations.

Main Methods:

  • Prospective cohort study of 87 CKD patients (NDD and DD) followed for 18 months.
  • Recorded newly occurred CV events.
  • Utilized Cox regression analysis to identify significant predictors of CV outcome.

Main Results:

  • Serum albumin, urea, interventricular septum thickness diameter (IVST), calcium antagonist use, and erythropoiesis-stimulating agent use were significant predictors of CV outcome.
  • Biomarkers of inflammation, oxidative stress, acute kidney injury (IL-18, CRP, ferritin, IMA, SOD, NGAL, KIM-1), and miR-133a did not show significant differences related to CV events or left ventricular hypertrophy.
  • Serum albumin, urea, IVST, calcium antagonist, and erythropoiesis-stimulating agents are associated with CV events in CKD.

Conclusions:

  • Serum albumin, urea, IVST, and specific medications are associated with CV events in CKD patients.
  • Current inflammation, oxidative stress, and acute kidney injury biomarkers are not significantly different in CKD patients with or without CV events.
  • Further research is needed to discover reliable cardiotoxicity biomarkers in CKD.

Keywords:
acute renal injurybiomarkerscardiovascular eventinflammationmicroRNAsoxidative stress

More Related Videos

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.2K
Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
418
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
265
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
145
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
164
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
91
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77